PCA
RARE icon

Providence Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Providence Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18
Closed -$1K – 424
2022
Q1 		$1K Buy
+18
New +$1.25K ﹤0.01% 433

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Providence Capital Advisors's RARE Position: Q2 2022 in Review

Providence Capital Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2022, closing a stake of 18 shares — an estimated $1K sold.

Providence Capital Advisors first reported a position in RARE in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 223 funds tracked by Wall St. Rank hold RARE as of Q2 2022.

  • Providence Capital Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Providence Capital Advisors sold 18 Ultragenyx Pharmaceutical shares in Q2 2022, an estimated $1K.
  • Providence Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2022 and held it in 1 quarter.
  • Providence Capital Advisors's Ultragenyx Pharmaceutical position peaked at $1K in Q1 2022.
  • 223 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2022.

Based on Providence Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.